, Hong Kong

HKEX greenlights Hangzhou Tigermed's IPO

The listing looks to raise about $1b.

Shenzhen-listed biotech firm Hangzhou Tigermed Consulting received Hong Kong Stock Exchange’s (HKEX) approval to conduct a second listing, a Bloomberg report revealed.

Hangzhou Tigermed could start gauging investor demand from next week. It is expected to raise about $1b, which would be the largest for a healthcare firm in Asia this year. Tigermed has already seen a 70% jump in its shares in Shenzhen.

Claiming to be the second-best performer of the year, Tigermed has partnered with a growing number of healthcare and pharmaceutical companies to sell shares at a record rate. Deliberations on Tigermed’s share sale are ongoing and details including size and timeline could still change.

Read more on Bloomberg.
 

Join Hong Kong Business community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!